Quantcast
Last updated on April 24, 2014 at 5:50 EDT

If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer

February 11, 2009

Genentech/Roche/Chugai’s Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai’s Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from GlaxoSmithKline’s Tykerb/Tyverb for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This is particularly true in the second- and subsequent HER2-positive treatment lines which are currently its most vulnerable market segments.

The new report entitled HER2-Positive Breast Cancer: Oncologists Are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting also finds that Genentech/Roche/Chugai’s pertuzumab in combination with Herceptin and Sanofi Aventis’ Taxotere will become Decision Resources’ proprietary clinical gold standard regimen for HER2-positive breast cancer by 2017. This will occur following its approval for the indication in combination with Herceptin and Taxotere in 2013.

“Based on surveys and interviews we conducted with U.S. and European oncologists, as well as comparative drug analysis using our proprietary drug comparator model, we concluded that pertuzumab will have competitive advantages in efficacy when used in combination with Herceptin and Taxotere versus using Herceptin and Taxotere alone,” stated Niamh Murphy, Ph.D., analyst at Decision Resources.

About the Report

HER2-Positive Breast Cancer: Oncologists are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com

SOURCE Decision Resources


Source: newswire